Krystal Biotech (KRYS) Cash from Investing Activities (2021 - 2026)
Krystal Biotech (KRYS) has disclosed Cash from Investing Activities for 5 consecutive years, with $11.2 million as the latest value for Q4 2025.
- Quarterly Cash from Investing Activities rose 113.32% to $11.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$58.4 million through Dec 2025, up 64.26% year-over-year, with the annual reading at -$58.4 million for FY2025, 64.26% up from the prior year.
- Cash from Investing Activities hit $11.2 million in Q4 2025 for Krystal Biotech, up from -$4.3 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $105.2 million in Q3 2023 to a low of -$126.5 million in Q4 2021.
- Historically, Cash from Investing Activities has averaged -$24.0 million across 5 years, with a median of -$17.7 million in 2023.
- Biggest five-year swings in Cash from Investing Activities: crashed 7384.34% in 2022 and later skyrocketed 813.5% in 2023.
- Year by year, Cash from Investing Activities stood at -$126.5 million in 2021, then surged by 95.88% to -$5.2 million in 2022, then crashed by 95.08% to -$10.2 million in 2023, then tumbled by 724.59% to -$83.8 million in 2024, then soared by 113.32% to $11.2 million in 2025.
- Business Quant data shows Cash from Investing Activities for KRYS at $11.2 million in Q4 2025, -$4.3 million in Q3 2025, and -$10.5 million in Q2 2025.